{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:43:34Z","timestamp":1792269814353,"version":"4.4.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Janssen Global Services LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ard.2026.01.009","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T20:49:47Z","timestamp":1770929387000},"page":"911-920","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["A phase 2, randomised, placebo-controlled study of guselkumab in adults with new-onset or relapsing giant cell arteritis"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4523-8525","authenticated-orcid":false,"given":"Jean-Paul","family":"Makhzoum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C.","family":"Cid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Samson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Henes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Sch\u00f6nau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Espigol-Frigole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Ahlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Chun","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Verdijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Okonkwo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Grayson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Blockmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ard.2026.01.009_bib0001","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41572-021-00327-5","article-title":"Large-vessel vasculitis","volume":"7","author":"Pugh","year":"2022","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.ard.2026.01.009_bib0002","first-page":"119","article-title":"2016 ACR revised criteria for early diagnosis of giant cell (temporal) arteritis","volume":"3","author":"Salehi-Abari","year":"2016","journal-title":"Autoimmune Dis Ther Approaches Open Access"},{"issue":"9","key":"10.1016\/j.ard.2026.01.009_bib0003","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrrheum.2012.97","article-title":"Clinical features of polymyalgia rheumatica and giant cell arteritis","volume":"8","author":"Salvarani","year":"2012","journal-title":"Nat Rev Rheumatol"},{"issue":"Suppl 2","key":"10.1016\/j.ard.2026.01.009_bib0004","doi-asserted-by":"crossref","first-page":"ii32","DOI":"10.1093\/rheumatology\/kex424","article-title":"Large-vessel giant cell arteritis: diagnosis, monitoring and management","volume":"57","author":"Koster","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.ard.2026.01.009_bib0005","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/01.md.0000180043.19285.54","article-title":"Giant cell arteritis: laboratory tests at the time of diagnosis in a series of 240 patients","volume":"84","author":"Gonzalez-Gay","year":"2005","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.ard.2026.01.009_bib0006","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12877-019-1225-9","article-title":"Giant cell arteritis: is the clinical spectrum of the disease changing?","volume":"19","author":"Gonz\u00e1lez-Gay","year":"2019","journal-title":"BMC Geriatr"},{"issue":"2","key":"10.1016\/j.ard.2026.01.009_bib0007","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.mcna.2012.12.006","article-title":"Giant cell arteritis","volume":"97","author":"Waldman","year":"2013","journal-title":"Med Clin North Am"},{"issue":"10","key":"10.1016\/j.ard.2026.01.009_bib0008","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1016\/j.mayocp.2022.03.010","article-title":"Indirect comparison of glucocorticoid-sparing agents for remission maintenance in giant cell arteritis: a network meta-analysis","volume":"97","author":"Mainbourg","year":"2022","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.ard.2026.01.009_bib0009","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018 Update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.01.009_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/EB.S170388","article-title":"Giant cell arteritis: early diagnosis is key","volume":"11","author":"Baig","year":"2019","journal-title":"Eye Brain"},{"issue":"5","key":"10.1016\/j.ard.2026.01.009_bib0011","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/art.11388","article-title":"Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes","volume":"49","author":"Proven","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2026.01.009_bib0012","series-title":"ACTEMRA (tocilizumab) injection, for intravenous or subcutaneous use","year":"2025"},{"issue":"2","key":"10.1016\/j.ard.2026.01.009_bib0013","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000570","article-title":"Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients","volume":"3","author":"Prieto-Gonz\u00e1lez","year":"2017","journal-title":"RMD Open"},{"issue":"4","key":"10.1016\/j.ard.2026.01.009_bib0014","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ard.2026.01.009_bib0015","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/art.40876","article-title":"Glucocorticoid dosages and acute-phase reactant levels at giant cell arteritis flare in a randomized trial of tocilizumab","volume":"71","author":"Stone","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2026.01.009_bib0016","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13075-023-03177-6","article-title":"A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis","volume":"25","author":"Schmidt","year":"2023","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.ard.2026.01.009_bib0017","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.semarthrit.2018.04.004","article-title":"Ustekinumab for refractory giant cell arteritis: a prospective 52-week trial","volume":"48","author":"Conway","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.ard.2026.01.009_bib0018","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/acr.24200","article-title":"Ustekinumab for the treatment of giant cell arteritis","volume":"73","author":"Matza","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"10.1016\/j.ard.2026.01.009_bib0019","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1136\/annrheumdis-2021-221865","article-title":"Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"81","author":"Cid","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ard.2026.01.009_bib0020","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1016\/S2665-9913(23)00101-7","article-title":"Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"5","author":"Venhoff","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ard.2026.01.009_bib0021","series-title":"Novartis provides update on Phase III GCAptAIN study of Cosentyx in giant cell arteritis (GCA)","year":"2025"},{"key":"10.1016\/j.ard.2026.01.009_bib0022","unstructured":"Novartis Pharmaceuticals. Efficacy and safety of secukinumab in patients with new onset of giant cell arteritis who are in clinical resmission (GigAINt). [updated December 22, 2025; cited February 5, 2026]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05380453"},{"issue":"20","key":"10.1016\/j.ard.2026.01.009_bib0023","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa2413449","article-title":"A phase 3 trial of upadacitinib for giant-cell arteritis","volume":"392","author":"Blockmans","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ard.2026.01.009_bib0024","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ard.2026.01.009_bib0025","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1136\/annrheumdis-2018-213488","article-title":"Interleukin 12 and interleukin 23 play key pathogenic roles in inflammatory and proliferative pathways in giant cell arteritis","volume":"77","author":"Conway","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.ard.2026.01.009_bib0026","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1002\/art.34647","article-title":"Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis","volume":"64","author":"Samson","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.ard.2026.01.009_bib0027","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3390\/cells13030267","article-title":"Giant cell arteritis: advances in understanding pathogenesis and implications for clinical practice","volume":"13","author":"Paroli","year":"2024","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.ard.2026.01.009_bib0028","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1136\/annrheumdis-2014-207116","article-title":"DNA methylation analysis of the temporal artery microenvironment in giant cell arteritis","volume":"75","author":"Coit","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.ard.2026.01.009_bib0029","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1136\/annrheumdis-2014-205261","article-title":"Influence of the IL17A locus in giant cell arteritis susceptibility","volume":"73","author":"M\u00e1rquez","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.ard.2026.01.009_bib0030","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1161\/CIRCULATIONAHA.109.872903","article-title":"Th17 and Th1 T-cell responses in giant cell arteritis","volume":"121","author":"Deng","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ard.2026.01.009_bib0031","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3389\/fimmu.2018.00809","article-title":"Expression and function of IL12\/23 related cytokine subunits (p35, p40, and p19) in giant-cell arteritis lesions: contribution of p40 to Th1- and Th17-mediated inflammatory pathways","volume":"9","author":"Esp\u00edgol-Frigol\u00e9","year":"2018","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.ard.2026.01.009_bib0032","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-\u03b3t+ CD3+CD4-CD8- entheseal resident T cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.ard.2026.01.009_bib0033","series-title":"TREMFYA (guselkumab) injection, for subcutaneous use","year":"2025"},{"issue":"Suppl 1","key":"10.1016\/j.ard.2026.01.009_bib0034","doi-asserted-by":"crossref","first-page":"i025","DOI":"10.1093\/ecco-jcc\/jjab232.022","article-title":"OP23 The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active ulcerative colitis: phase 2b QUASAR study results through week 12","volume":"16","author":"Dignass","year":"2022","journal-title":"J Crohns Colitis"},{"issue":"6","key":"10.1016\/j.ard.2026.01.009_bib0035","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1053\/j.gastro.2022.01.047","article-title":"Guselkumab for the treatment of Crohn\u2019s disease: induction results from the phase 2 GALAXI-1 study","volume":"162","author":"Sandborn","year":"2022","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.ard.2026.01.009_bib0036","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/art.40379","article-title":"18F-fluorodeoxyglucose-positron emission tomography as an imaging biomarker in a prospective, longitudinal cohort of patients with large vessel vasculitis","volume":"70","author":"Grayson","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.ard.2026.01.009_bib0037","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2967\/jnumed.121.262326","article-title":"Comparing semiquantitative and qualitative methods of vascular 18F-FDG PET activity measurement in large-vessel vasculitis","volume":"63","author":"Dashora","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ard.2026.01.009_bib0038","article-title":"No significant effects of IL-23 on initiating and perpetuating the axial spondyloarthritis: the reasons for the failure of IL-23 inhibitors","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"issue":"419","key":"10.1016\/j.ard.2026.01.009_bib0039","doi-asserted-by":"crossref","first-page":"ra28","DOI":"10.1126\/scisignal.aad2357","article-title":"Identification of IL-23p19 as an endothelial proinflammatory peptide that promotes gp130-STAT3 signaling","volume":"9","author":"Esp\u00edgol-Frigol\u00e9","year":"2016","journal-title":"Sci Signal"},{"issue":"8","key":"10.1016\/j.ard.2026.01.009_bib0040","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1093\/rheumatology\/keab332","article-title":"Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study","volume":"60","author":"Sch\u00f6nau","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.ard.2026.01.009_bib0041","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187995","article-title":"Internal tissue references for 18Fluorodeoxyglucose vascular inflammation imaging: implications for cardiovascular risk stratification and clinical trials","volume":"12","author":"Ahlman","year":"2017","journal-title":"PLoS One"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726000130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726000130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:03:14Z","timestamp":1792267394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496726000130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0003496726000130"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2026.01.009","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 2, randomised, placebo-controlled study of guselkumab in adults with new-onset or relapsing giant cell arteritis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2026.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}